title: Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.
abstract: Disseminated malignant melanoma has a poor prognosis. Immunotherapy based on cytokines or checkpoint inhibitors has a protracted beneficial effect in a select group of patients. Understanding the mechanisms that inhibit tumor-specific T cells will help the development of biomarkers to formulate therapy for this disease. Clin Cancer Res; 20(6); 1401-3. ©2014 AACR.
authors: Authors' Affiliation: Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden.
authors: Rolf
authors: R
authors: Kiessling
authors: Yumeng
authors: Y
authors: Mao
authors: Yago
authors: Y
authors: Pico de Coaña
mesh_terms: D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D022423:Myeloid Cells / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*